461 related articles for article (PubMed ID: 24168751)
1. Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.
Leman LJ; Maryanoff BE; Ghadiri MR
J Med Chem; 2014 Mar; 57(6):2169-96. PubMed ID: 24168751
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein Mimetic Peptides as Modulators of Lipoprotein Function.
Anantharamaiah GM; Garber DW; White CR
Protein Pept Lett; 2016; 23(11):1024-1031. PubMed ID: 27586181
[TBL] [Abstract][Full Text] [Related]
3. The promise of apolipoprotein A-I mimetics.
Mendez AJ
Curr Opin Endocrinol Diabetes Obes; 2010 Apr; 17(2):171-6. PubMed ID: 20125002
[TBL] [Abstract][Full Text] [Related]
4. Lipid-free Apolipoprotein A-I Structure: Insights into HDL Formation and Atherosclerosis Development.
Mei X; Atkinson D
Arch Med Res; 2015 Jul; 46(5):351-60. PubMed ID: 26048453
[TBL] [Abstract][Full Text] [Related]
5. An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice.
Ditiatkovski M; D'Souza W; Kesani R; Chin-Dusting J; de Haan JB; Remaley A; Sviridov D
PLoS One; 2013; 8(7):e68802. PubMed ID: 23874769
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.
Osei-Hwedieh DO; Amar M; Sviridov D; Remaley AT
Pharmacol Ther; 2011 Apr; 130(1):83-91. PubMed ID: 21172387
[TBL] [Abstract][Full Text] [Related]
7. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.
Amar MJ; D'Souza W; Turner S; Demosky S; Sviridov D; Stonik J; Luchoomun J; Voogt J; Hellerstein M; Sviridov D; Remaley AT
J Pharmacol Exp Ther; 2010 Aug; 334(2):634-41. PubMed ID: 20484557
[TBL] [Abstract][Full Text] [Related]
8. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.
Anantharamaiah GM; Mishra VK; Garber DW; Datta G; Handattu SP; Palgunachari MN; Chaddha M; Navab M; Reddy ST; Segrest JP; Fogelman AM
J Lipid Res; 2007 Sep; 48(9):1915-23. PubMed ID: 17570869
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.
Wool GD; Reardon CA; Getz GS
J Lipid Res; 2008 Jun; 49(6):1268-83. PubMed ID: 18323574
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein A-I Mimetic Peptides: Discordance Between In Vitro and In Vivo Properties-Brief Report.
Ditiatkovski M; Palsson J; Chin-Dusting J; Remaley AT; Sviridov D
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1301-1306. PubMed ID: 28522696
[TBL] [Abstract][Full Text] [Related]
11. A Photo-Activatable Peptide Mimicking Functions of Apolipoprotein A-I.
Kawahara H; Miyashita N; Tachibana K; Tsuda Y; Morimoto K; Tsuji K; Shigenaga A; Otaka A; Ishida T; Okuhira K
Biol Pharm Bull; 2019; 42(6):1019-1024. PubMed ID: 31155576
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein A-I mimetic peptides.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Yu N; Ansell BJ; Datta G; Garber DW; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1325-31. PubMed ID: 15831812
[TBL] [Abstract][Full Text] [Related]
13. ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose.
Carballo-Jane E; Chen Z; O'Neill E; Wang J; Burton C; Chang CH; Chen X; Eveland S; Frantz-Wattley B; Gagen K; Hubbard B; Ichetovkin M; Luell S; Meurer R; Song X; Strack A; Langella A; Cianetti S; Rech F; Capitò E; Bufali S; Veneziano M; Verdirame M; Bonelli F; Monteagudo E; Pessi A; Ingenito R; Bianchi E
Bioorg Med Chem; 2010 Dec; 18(24):8669-78. PubMed ID: 21115285
[TBL] [Abstract][Full Text] [Related]
14. Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins.
Garber DW; Handattu SP; Datta G; Mishra VK; Gupta H; White CR; Anantharamaiah GM
Curr Pharm Biotechnol; 2006 Aug; 7(4):235-40. PubMed ID: 16918400
[TBL] [Abstract][Full Text] [Related]
15. [Role of apolipoprotein AI on nascent high-density lipoprotein particle formation].
Wu JF; Tang YY; Zeng GF; Tang CK
Sheng Li Ke Xue Jin Zhan; 2014 Apr; 45(2):81-6. PubMed ID: 25069300
[TBL] [Abstract][Full Text] [Related]
16. Branched synthetic constructs that mimic the physico-chemical properties of apolipoprotein AI in reconstituted high-density lipoproteins.
Demoor L; Boutillon C; Fievet C; Vanloo B; Baert J; Rosseneu M; Fruchart JC; Tartar A
Eur J Biochem; 1996 Jul; 239(1):74-84. PubMed ID: 8706721
[TBL] [Abstract][Full Text] [Related]
17. Reversal of atherosclerosis with apolipoprotein A1: back to basics.
Smits LP; Kootte RS; Stroes ES
Atherosclerosis; 2014 Jan; 232(1):217-9. PubMed ID: 24401241
[No Abstract] [Full Text] [Related]
18. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
[TBL] [Abstract][Full Text] [Related]
19. Biological properties of apolipoprotein a-I mimetic peptides.
Getz GS; Wool GD; Reardon CA
Curr Atheroscler Rep; 2010 Mar; 12(2):96-104. PubMed ID: 20425244
[TBL] [Abstract][Full Text] [Related]
20. HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders.
Getz GS; Wool GD; Reardon CA
Curr Pharm Des; 2010; 16(28):3173-84. PubMed ID: 20687877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
